版权说明 帮助中心
首页 > 成果 > 详情

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

ESI高被引SCI-EMedline
WOS被引频次:112
认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Birdwell, K. A.*;Decker, B.;Barbarino, J. M.;Peterson, J. F.;Stein, C. M.;Sadee, W.;Wang, D.;Vinks, A. A.;He, Y.;Swen, J. J.;Leeder, J. S.;van Schaik, R. H. N.;Thummel, K. E.;Klein, T. E.;Caudle, K. E.;MacPhee, I. A. M.
通讯作者:
Birdwell, K. A.
作者机构:
[Birdwell, K. A.] Vanderbilt Univ, Dept Med, Div Nephrol, Nashville, TN 37235 USA.
[Stein, C. M.; Peterson, J. F.; Birdwell, K. A.] Vanderbilt Univ, Dept Med, Nashville, TN 37235 USA.
[Decker, B.] Indiana Univ, Sch Med, Div Nephrol, Indianapolis, IN USA.
[Decker, B.] Indiana Univ, Sch Med, Div Clin Pharmacol, Indianapolis, IN USA.
[Klein, T. E.; Barbarino, J. M.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA.
通讯机构:
[Birdwell, K. A.] Vanderbilt Univ, Dept Med, Div Nephrol, Nashville, TN 37235 USA.
语种:
英文
期刊:
Clinical Pharmacology & Therapeutics
ISSN:
1532-6535
年:
2015
卷:
98
期:
1
页码:
19-24
文献类别:
WOS:Article
所属学科:
ESI学科类别:药理学&毒理学;WOS学科类别:Pharmacology & Pharmacy
入藏号:
基金类别:
National Institutes of Health/National Institute of General Medical Science (NIH/NIGMS) [U01 GM92666, R24 GM61374, U01 HL0105198]; NIH [GM109145, U01 GM092655, K23 GM100183, UL1TR000445, U01 GM092676]
机构署名:
本校为其他机构
院系归属:
湘雅药学院
摘要:
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).
参考文献:
Bouamar R, 2013, AM J TRANSPLANT, V13, P1253, DOI 10.1111/ajt.12191
Bowman LJ, 2008, EXPERT OPIN PHARMACO, V9, P635, DOI 10.1517/14656566.9.4.635
Braun F, 2002, TRANSPLANT P, V34, P1538, DOI 10.1016/S0041-1345(02)03010-5
Chandel N, 2009, PHARMACOGENET GENOM, V19, P458, DOI 10.1097/FPC.0b013e32832bd085
de Wildt SN, 2011, EUR J CLIN PHARMACOL, V67, P1231, DOI 10.1007/s00228-011-1083-7

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com